Tapestry News (NASDAQ:TPPH)
| Latest Tapestry Pharmaceuticals News Headlines | | Date | Time | Source | | | 04/08/2008 | 4:30PM | PRNUS | Tapestry Receives Nasdaq Delisting Notice
BOULDER, Colo., April 8, 2008 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) today announced that it had received a letter from the Nasdaq Stock Market ("Nasdaq") formally notifying it that Nasdaq has not received Tapestry's Form 10-K for the period ended January 2, 2008, as required by Marketplace... More...>> |
| 12/21/2007 | 3:37PM | PRNUS | Tapestry Receives Notice Regarding Minimum Bid Price Rule
BOULDER, Colo., Dec. 21 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) today announced that it received notice on December 18, 2007 from the Nasdaq Stock Market that the minimum bid price of its common stock had fallen below $1.00 for 30 consecutive business days and that Tapestry was therefore... More...>> |
| 12/05/2007 | 11:06AM | PRNUS | Eric Rowinsky, M.D. and Martin Cannon Join Tapestry Board of Directors
BOULDER, Colo., Dec. 5 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) today announced the appointment of Eric K. Rowinsky, M.D., and Martin Cannon to the Company's Board of Directors. Dr. Rowinsky is Senior Vice President and Chief Medical Officer for ImClone Systems, Inc. Mr. Cannon is the... More...>> |
| 11/05/2007 | 8:00AM | PRNUS | Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
60% of second line HRPC patients on TPI 287 show clinical benefit
BOULDER, Colo., Nov. 5 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) announced today financial results for the third quarter ended September 26, 2007.
The net loss for the third quarter of 2007 was $6.1 million, or $0.37 per... More...>> |
| 10/29/2007 | 4:24PM | PRNUS | Tapestry Pharmaceuticals to Present at The Acumen BioFin Rodman & Renshaw Healthcare Conference
BOULDER, Colo., Oct. 29 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) announced today that management will provide a company update at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 5, 2007 at 9:50 a.m. Eastern Time. The conference is being held at The New York... More...>> |
| 10/29/2007 | 8:00AM | PRNUS | Tapestry to Host Conference Call on November 5th to Discuss Third Quarter 2007 Financial Results
BOULDER, Colo., Oct. 29 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) announced today that it will host a conference call on Monday, November 5, 2007 at 12:00 p.m. Eastern Time (10:00 a.m. Mountain Time) to review the Company's third quarter 2007 financial results and provide a company update... More...>> |
| 10/26/2007 | 8:00AM | PRNUS | Tapestry Announces Strategy to Focus on TPI 287 Clinical Program
Company downsizing non-clinical workforce
BOULDER, Colo., Oct. 26 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH), announced today a plan to focus all of its resources on advancing TPI 287's on-going and previously announced clinical trials. As part of the strategic plan, Tapestry is reducing... More...>> |
| 10/23/2007 | 3:30PM | PRNUS | Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
BOULDER, Colo., Oct. 23 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH), is presenting data today at the AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This year's conference is being held October 22-26, 2007 at the Moscone Convention Center, San Francisco... More...>> |
| 10/03/2007 | 8:00AM | PRNUS | Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer
BOULDER, Colo., Oct. 3 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) announced today that it has initiated a Phase 2 open- label, multi-center study of TPI 287 in patients with advanced pancreatic cancer. This is the second Phase 2 trial exploring the activity of TPI 287 in various tumor types:... More...>> |
| 09/11/2007 | 8:00AM | PRNUS | Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
NEW YORK, Sept. 11 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH). The full 60-page report can be found at http://www.crystalra.com/.
Tapestry Pharmaceuticals, Inc. ("Tapestry" or "the... More...>> |
| 09/11/2007 | 6:00AM | PRNUS | Vista Partners Updates Coverage on Tapestry Pharmaceuticals
LOS ANGELES, Sept. 11 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Tapestry Pharmaceuticals (NASDAQ:TPPH). Ross Silver, Director of Research for Vista Partners stated, "Tapestry's lead compound TPI-287 showed promise in Phase I trials. We were particularly encouraged by activity in... More...>> |
| 08/09/2007 | 8:00AM | PRNUS | Tapestry Reports Second Quarter 2007 Results
Results Reflect Continued Investment in Clinical Development of TPI 287
BOULDER, Colo., Aug. 9 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) announced today financial results for the second quarter ended June 27, 2007.
The net loss for the second quarter of 2007 was $6.2 million, or $0.37 per... More...>> |
| 08/02/2007 | 1:00PM | PRNUS | Tapestry to Host Conference Call on August 9th to Discuss Second Quarter 2007 Financial Results
BOULDER, Colo., Aug. 2 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) announced today that it will host a conference call on Thursday, August 9, 2007 at 9:00 a.m. Eastern Time (7:00 a.m. Mountain Time) to review the Company's second quarter 2007 financial results and provide a company update... More...>> |
| 06/12/2007 | 5:30PM | PRNUS | Tapestry Pharmaceuticals Withdraws Registration Statement for Public Offering
BOULDER, Colo., June 12 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) announced today that it has withdrawn its registration statement on Form S-1 that had been filed with the SEC in conjunction with a proposed offering of $40 million of common stock.
"Given the encouraging data we recently... More...>> |
| 06/08/2007 | 9:30AM | PRNUS | Callisto Pharmaceuticals Files Suit Against Former Executive Vice President for Breach of Employment Agreement, Fraud, Conversio
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a biopharmaceutical company focused on the development of new drugs to treat cancer and inflammatory diseases, announced today that it has filed a complaint against Donald Picker, its former Executive Vice President, Research... More...>> |
| 06/07/2007 | 7:00AM | PRNUS | Tapestry Pharmaceuticals to Present at the Needham & Company Biotechnology and Medical Technology Conference
BOULDER, Colo., June 7 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) announced today that management will provide a company update at the 6th Annual Needham & Company Biotechnology and Medical Technology Conference on Wednesday, June 13th, 2007 at 2:00 p.m. EDT. The conference is being held... More...>> |
| 06/03/2007 | 9:00AM | PRNUS | Tapestry Pharmaceuticals Presents Phase I Data on TPI 287 at the 43rd ASCO Annual Meeting
BOULDER, Colo., June 3 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) today presented data from two Phase I clinical trials of TPI 287, the Company's leading drug candidate, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. In these two Phase I studies... More...>> |
| 05/29/2007 | 7:00AM | PRNUS | Tapestry Pharmaceuticals To Present at the Banc of America 2007 Health Care Conference
BOULDER, Colo., May 29 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) announced today that management will provide a company update at the Banc of America 2007 Health Care Conference on May 31, 2007 at 3:20 p.m. PDT. The conference is being held at the Four Seasons Las Vegas, NV. A live audio... More...>> |
| 05/14/2007 | 8:00AM | PRNUS | Tapestry Pharmaceuticals to Present Data on TPI 287 at the 43rd ASCO Annual Meeting
BOULDER, Colo., May 14 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) today announced that data from two Phase I trials of TPI 287, the Company's lead product candidate, will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. on Sunday... More...>> |
| 05/09/2007 | 7:01AM | PRNUS | Tapestry Pharmaceuticals Announces Phase II Clinical Program for TPI 287
BOULDER, Colo., May 9 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (NASDAQ:TPPH) today announced the company's planned Phase II clinical trial program for its next generation taxane, TPI 287. The Company recently opened enrollment in a Phase II clinical trial in patients with hormone refractory prostate... More...>> |
|
|
|